CD19 and Encephalopathy: Additionally, limiting adverse effects, including severe cytokine release syndrome, encephalopathy, persistent B cell aplasia (in the case of anti-CD19 CAR-T cells), or death, related to other forms of cellular therapy are usually not associated with NK cells38–41.